Ledger.Open graph →
SEC Form D · Amendment · filed January 3, 2022

Nacuity Pharmaceuticals, Inc

Offering
$17.4M
Sold
$11.6M
Exemption
Rule 506(b)
Industry
Biotechnology
Location
FORT WORTH, TX
Type

Rule 506(b): private placement to accredited investors, no public advertising.

People & firms on this filing (21)

Charles Lieser · Fort Worth, TXExecDavid Wohlberg · Fort Worth, TXExec · DirectorRobert Ruffolo · Fort Worth, TXDirectorGerald Cagle · Fort Worth, TXDirectorRobin Steel · Fort Worth, TXDirectorHalden Conner · Fort Worth, TXExec · DirectorBenjamin Yerxa · Fort Worth, TXDirectorPeter G. Davies · Columbus, OHDirectorJack Mitchell · Gladstone, MOExecAndrew F. Bohutinsky · Columbus, OHDirectorThomas R. Utgard · Columbus, OHDirectorRochael Adranly · San Francisco, CAExec · Director(General Partner) Poplar Forest Capital LLC · Pasadena, CADirectorStonehenge Partners Corp · Columbus, OHExec · DirectorSteve Carpenter · Boulder, COExec · DirectorLaurence P. Sellyn · Village of Golf, FLExecSound Point Meridian Fund GP LLC · New York, NYDirectorVincent Molinari · Woodbury, NYExec · DirectorKavita Gupta · Woodbury, NYDirectorThomas Krane · Somerville, MADirectorNiloofar Howe · Somerville, MADirector

Public SEC Form D (Reg D) filing. · View issuer on SEC EDGAR ↗